United States Hereditary Genetic Testing Market is
anticipated to witness a steady CAGR in
the forecast period, 2024-2028. This
can be ascribed to the growing frequency of hereditary disorders in the US.
Similarly, growing advancements in genetic analysis and the advent of rare
diseases are expected to drive the growth of the market during the forecast
period. Additionally, growing concern about women’s health will enhance the
demand for the US hereditary genetic testing market over the years. Also, the
growing existence of significant businesses offering genetic tests, the
widespread use of modern therapies, and government guidelines to maintain the
integrity of hereditary genetic testing screening are expected to drive the
growth of the market in the forecast period.
Rising
Prevalence of Chronic Disorders
Growing
incidence of genetic disorders and cancer rapidly across the US will further increase
the demand for US hereditary genetic
testing market during the forecast period. One of the major factors is early
and preventive care which is expected to drive the growth of the market in the
forecast period. Also, the growing economic burden for the treatment of
diseases is leading to a stronger focus of healthcare providers and government
bodies towards the early diagnosis and screening for health risks. According to the American
Cancer Society, almost 1.8 million new patients with cancer were diagnosed in
2020. Around 606,520 cancer deaths were reported in the United States in 2020,
making cancer the second-highest
death-causing disease worldwide. Various types of cancers are inherited from generation to
generation due to gene mutations. So, genetic testing is widely used for
studying the pattern and prevention of gene mutation, treatment of diseases,
and drug discovery. Similarly, cytogenetics helps to study chromosomes to
provide a better knowledge of cancers such as breast cancer.
Growing
Demand for Personalized Medicine
Growing
demand for personalized medicine for treating individual patients’ diseases
will further drive the growth of the market over the years. So, large-scale
drug discovery is necessary for increasing the feasibility and practicality of
personalized medicines for the detection of genetic disorders as well as
diseases. Genetic testing is used in pharmacogenomics for drug-gene testing,
and it can help to accelerate drug development. So, researchers are more aware of
the treatments of customized diseases by using genetic testing techniques such
as cytogenetic testing (fluorescence in situ hybridization, microarray, and
others), biochemical testing, molecular testing, and DNA sequencing. Moreover, the growing demand for primary patient
care by physicians using genetic testing is expected to rise the demand for the
hereditary genetic testing market over the years. In addition, consumer
awareness of personalized medicines increased to 33% in 2019 from 29% in 2018.
Download Free Sample Report
Growing
Advancement in Genetic Testing
Growing
advancements in genetic testing such as the use of chromosomal microarray
analysis and biochip for the detection of genetic disorders including NGS
transforms the method of determination of structural and numerical
abnormalities in chromosomes and this in turn leads to the detection of various
type of rare genetic disorders and drives the growth of the market over the
years. Technological advancements also contribute towards developing the
non-invasive cell-free fatal DNA for identifying sub chromosomal abnormalities,
single gene disorders and chromosomal aneuploidy, which will further propel the
growth of the market. Further, these technologies contribute towards the development
of carrier screens that allow the simultaneous detection of different genetic disorders.
In September 2019, Roche launched a blood-based genomic profiling test,
FoundationOne Liquid and this test can detect 70 most common mutated genes in
solid tumors and microsatellite instability. These
types of development in genetic testing products by major key players are expected
to drive the growth for the hereditary
genetic testing market during the forecast period.
Market
Segmentation
United States Hereditary Genetic Testing market can be segmented by technique, application, payer, end user,
region and competitive landscape.. Based on technique, the market can be
segmented into PCR, DNA Sequencing, Microarrays, Others.
Based on application, the market can be differentiated into Cardiology,
Oncology, Pharmacogenomics, Cognitive Dysfunction, Pathogenomics, Others. Based
on payer, the market can be differentiated into Public Health Insurance,
Private Health Insurance, Out of Pocket. Based on end user, the market can be
divided into Hospitals, Independent Laboratories.
Recent Development
- For instance, in July 2020, Myriad
Genetics, Inc. launched proprietary AMPLIFY technology, which increases
performance of its Prequel noninvasive prenatal screening (NIPS) test.
- In addition, Myriad also launched New
GeneSight psychotropic patient collection kit in June 2020. This kit allows DNA
sample collection, typically administered in a clinician’s office, to be
completed at home.
Market Players
Invitae Corporation,
Ambry Genetics, BioReference Laboratories Inc, Progenity Inc., Pathema Gx Lab,
LLC., Quest Diagnostics Incorporated, Myriad Genetics Inc., Fulgent Genetics,
Inc., Burning Rock Biotech Limited are some of the leading players operating in the United States Hereditary Genetic Testing market.
|
Attribute
|
Details
|
|
Base
Year
|
2022
|
|
Historic
Data
|
2018 – 2021
|
|
Estimated
Year
|
2023
|
|
Forecast
Period
|
2024 – 2028
|
|
Quantitative
Units
|
Revenue in USD Million, Volume in Units, and CAGR for 2018-2022
and 2023-2028
|
|
Report
Coverage
|
Revenue
forecast, volume forecast, company share, competitive landscape, growth
factors, and trends
|
|
Segments
Covered
|
By Technique
By Application
By Payer
By End User
By Region
|
|
Regional
scope
|
Northeast;
Mid-West; West; South
|
|
Key
companies profiled
|
Invitae Corporation, Ambry Genetics, BioReference
Laboratories Inc.Progenity Inc., Pathema Gx Lab, LLC., Quest Diagnostics
Incorporated, Myriad Genetics Inc., Fulgent Genetics,Inc., Burning Rock
Biotech Limited.
|
|
Customization
scope
|
10%
free report customization with purchase. Addition or alteration to country,
regional & segment scope.
|
|
Pricing
and purchase options
|
Avail customized purchase options to meet your exact research
needs. Explore purchase options
|
|
Delivery
Format
|
PDF and Excel through Email (We can also provide the editable
version of the report in PPT/Word format on special request)
|
Report Scope:
In this report, United States Hereditary Genetic Testing market has been segmented into following
categories, in addition to the industry trends which have also been detailed
below:·
United
States Hereditary Genetic Testing Market,
By Technique:
o PCR
o DNA Sequencing
o Microarrays
o Others
·
United
States Hereditary Genetic Testing Market,
By Application:
o Cardiology
o Oncology
o Pharmacogenomics
o Cognitive Dysfunction
o Pathogenomics
o Others
·
United
States Hereditary Genetic Testing Market,
By Payer:
o Public Health Insurance
o Private Health Insurance
o Out of Pocket
·
United States Hereditary Genetic Testing Market, By End User:
o Hospitals
o Independent Laboratories
·
United
States Hereditary Genetic Testing Market,
By Region:
o Northeast
o Mid-west
o West
o South
Competitive Landscape
Company
Profiles: Detailed
analysis of the major companies present in the United States Hereditary Genetic Testing Market.
Available Customizations:
With the given market data, TechSci
Research offers customizations according to a company’s specific needs. The following
customization options are available for the report:
Company Information
- Detailed analysis and profiling of
additional market players (up to five).
United States Hereditary Genetic Testing Market is an upcoming report to be released soon. If you wish an early
delivery of this report or want to confirm the date of release, please contact
us at [email protected]